Scarica l'app Stockscreener
5.35
3.48%
0.18
Dopo l'orario di chiusura:
5.40
0.05
+0.93%
Precedente Chiudi:
$5.17
Aprire:
$5.2
Volume 24 ore:
3.93M
Relative Volume:
1.95
Capitalizzazione di mercato:
$951.56M
Reddito:
-
Utile/perdita netta:
$-45.44M
Rapporto P/E:
-15.29
EPS:
-0.35
Flusso di cassa netto:
$-42.28M
1 W Prestazione:
+3.48%
1M Prestazione:
+4.09%
6M Prestazione:
+95.26%
1 anno Prestazione:
+187.63%
Intervallo 1D:
$5.155
$5.695
Intervallo di 1 settimana:
$4.79
$5.695
Portata 52W:
$1.33
$5.86
Compass Therapeutics Inc Stock (CMPX) Company Profile
Nome
Compass Therapeutics Inc
Settore
Industria
Telefono
617-500-8099
Indirizzo
80 GUEST STREET, BOSTON
Confronta CMPX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.35 | 919.55M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | William Blair | Outperform |
| 2025-12-03 | Iniziato | Canaccord Genuity | Buy |
| 2025-12-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2025-04-02 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | Iniziato | Guggenheim | Buy |
| 2025-02-19 | Iniziato | Piper Sandler | Overweight |
| 2024-12-23 | Iniziato | D. Boral Capital | Buy |
| 2024-11-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | Iniziato | Jefferies | Buy |
| 2023-01-27 | Iniziato | Stifel | Buy |
| 2022-05-23 | Ripresa | H.C. Wainwright | Buy |
| 2022-03-15 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-01-19 | Iniziato | B. Riley Securities | Buy |
| 2021-12-22 | Iniziato | Raymond James | Outperform |
| 2021-12-20 | Iniziato | SVB Leerink | Outperform |
| 2021-12-15 | Iniziato | Wedbush | Outperform |
Mostra tutto
Compass Therapeutics Inc Borsa (CMPX) Ultime notizie
Lifesci Capital Has Strong Estimate for CMPX FY2025 Earnings - Defense World
Why Compass Therapeutics Inc. stock could outperform in 2025Market Trend Report & Scalable Portfolio Growth Ideas - ulpravda.ru
Will Compass Therapeutics Inc. stock benefit from green energy trendsQuarterly Profit Summary & Low Drawdown Momentum Ideas - ulpravda.ru
Is Compass Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Rallies & Capital Protection Trading Alerts - ulpravda.ru
Short Squeeze: Is Compass Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Daily Volume Surge Signals - ulpravda.ru
Will Compass Therapeutics Inc. stock benefit from commodity prices2025 Fundamental Recap & Weekly Breakout Watchlists - ulpravda.ru
How Compass Therapeutics Inc. stock reacts to global recession fearsEarnings Performance Report & Real-Time Buy Signal Notifications - ulpravda.ru
Is Compass Therapeutics Inc. stock a defensive play in 20252025 Pullback Review & Long-Term Growth Portfolio Plans - ulpravda.ru
Is Compass Therapeutics Inc. stock supported by strong fundamentals2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Biotech Powerhouse with 142.77% Upside Potential - DirectorsTalk Interviews
Why analysts remain bullish on Compass Therapeutics Inc. stock2025 Investor Takeaways & Reliable Entry Point Alerts - ulpravda.ru
Is Compass Therapeutics Inc. stock in correction or buying zoneMarket Capitalization Trends & Reinvest for Maximum Compounding Returns - ulpravda.ru
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Compass Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Compass Therapeutics details cash runway and pipeline progress - MSN
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com Canada
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com Canada
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com South Africa
Compass Therapeutics reports progress across cancer drug pipeline - Investing.com
Compass Therapeutics Provides Corporate Update - GlobeNewswire
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026 - MarketScreener
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care - One News Page
Compass Therapeutics announces key leadership appointments - MarketScreener
Compass Therapeutics appoints new chief commercial and medical officers - Investing.com
Compass Therapeutics Announces Key Leadership Appointments - The Manila Times
William Blair Initiates Compass Therapeutics at Outperform - MarketScreener
William Blair initiates coverage on Compass Therapeutics stock with Outperform rating - Investing.com Canada
Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study? - RTTNews
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - MSN
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next? - Defense World
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5%What's Next? - MarketBeat
Compass Therapeutics files for up to $400 million mixed shelf offeringSEC filing - MarketScreener
Compass Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Wedbush Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment - Insider Monkey
Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment - Finviz
Published on: 2025-12-21 11:19:43 - moha.gov.vn
Compass Therapeutics Earnings Notes - Trefis
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance
12 Best Multibagger Stocks to Buy Heading into 2026 - Insider Monkey
Patterns Watch: How Compass Therapeutics Inc. stock reacts to global recession fearsPrice Action & Low Risk Profit Maximizing Plans - DonanımHaber
How Compass Therapeutics Inc. stock trades during market volatilityWeekly Stock Recap & Comprehensive Market Scan Reports - Улправда
Signal Recap: Is Compass Therapeutics Inc. stock in correction or buying zone2025 Earnings Impact & Low Drawdown Investment Ideas - ulpravda.ru
Published on: 2025-12-19 03:17:09 - Улправда
Published on: 2025-12-19 02:57:37 - Улправда
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference - Yahoo Finance
Compass Therapeutics Inc Azioni (CMPX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Compass Therapeutics Inc Azioni (CMPX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):